Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136


Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.

Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH.

Lung Cancer. 2014 Jul;85(1):88-93. doi: 10.1016/j.lungcan.2014.04.005. Epub 2014 Apr 22.


Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.

Xu X, Duan L, Zhou B, Ma R, Zhou H, Liu Z.

Clin Exp Pharmacol Physiol. 2012 Sep;39(9):786-92. doi: 10.1111/j.1440-1681.2012.05741.x.


Tissue platinum concentration and tumor response in non-small-cell lung cancer.

Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH.

J Clin Oncol. 2012 Sep 20;30(27):3345-52. doi: 10.1200/JCO.2011.40.8120. Epub 2012 Aug 13.


ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.

Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.

Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693.


Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.

Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES.

Anticancer Res. 2016 Feb;36(2):495-501.


Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.

Xu X, Ren H, Zhou B, Zhao Y, Yuan R, Ma R, Zhou H, Liu Z.

Lung Cancer. 2012 Aug;77(2):438-42. doi: 10.1016/j.lungcan.2012.03.023. Epub 2012 Apr 17.


Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.


Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).

Li ZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ, Wang F, Wang ZQ, Zhang DS, Li YH, Xu RH.

J Transl Med. 2012 Feb 3;10:21. doi: 10.1186/1479-5876-10-21.


Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Blair BG, Larson CA, Safaei R, Howell SB.

Clin Cancer Res. 2009 Jul 1;15(13):4312-21. doi: 10.1158/1078-0432.CCR-09-0311. Epub 2009 Jun 9.


Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M.

Cancer Sci. 2003 Apr;94(4):394-9.


Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.

Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC.

Lung Cancer. 2012 Feb;75(2):228-34. doi: 10.1016/j.lungcan.2011.06.011. Epub 2011 Jul 23.


Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.

Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K, Kato H, Nishiwaki Y, Saijo N.

Lung Cancer. 2006 Nov;54(2):217-25. Epub 2006 Aug 24.


Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.

Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.

Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86. doi: 10.1007/s00280-014-2562-1. Epub 2014 Aug 9.


Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.

Zeng HZ, Qu YQ, Liang AB, Deng AM, Zhang WJ, Xiu B, Wang H, Wang H.

Neoplasma. 2011;58(5):449-54.


The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.

Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH.

Lung Cancer. 2010 Jun;68(3):478-83. doi: 10.1016/j.lungcan.2009.07.004. Epub 2009 Aug 15.


Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A.

Lung Cancer. 2009 Apr;64(1):98-104. doi: 10.1016/j.lungcan.2008.07.014. Epub 2008 Sep 26.


Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Schneider JG, Farhadfar N, Sivapiragasam A, Geller M, Islam S, Selbs E.

Oncologist. 2014 May;19(5):459-65. doi: 10.1634/theoncologist.2013-0311. Epub 2014 Apr 4.


[Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].

Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.

Ai Zheng. 2004 Jul;23(7):845-50. Chinese.


Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.

Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A.

Clin Cancer Res. 2004 Mar 1;10(5):1691-7.

Items per page

Supplemental Content

Write to the Help Desk